Autolus Therapeutics plc Cash Flow Conversion Efficiency

Latest as of June 2026: -0.335x

Autolus Therapeutics plc cash flow conversion efficiency. Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has a cash flow conversion efficiency ratio of -0.335x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-25.07 Million ≈ $-29.31 Million USD) by net assets (€74.84 Million ≈ $87.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Autolus Therapeutics plc (2017–2025)

Cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2025. This chart illustrates how Autolus Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Autolus Therapeutics plc (6A3A) stock price for real-time trading data and today's change.

Autolus Therapeutics plc Cash Flow Conversion Ratio Explained

Autolus Therapeutics plc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Autolus Therapeutics plc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Autolus Therapeutics plc ranked by their cash flow conversion efficiency. Also see Autolus Therapeutics plc (6A3A) total market value for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Salmones Camanchaca S.A SN:SALMOCAM	-0.019x
Summit Midstream Corporation NYSE:SMC	0.008x
Zhuhai Kles Technology Co. Ltd. A SHE:301314	N/A
TPI Polene Power Public Company Limited BK:TPIPP	0.000x
High Liner Foods Incorporated TO:HLF	-0.007x
Jiangsu WELLE Environmental Co Ltd SHE:300190	0.016x
China BlueChemical Ltd F:H1Q	0.009x
Verra Mobility Corp NASDAQ:VRRM	0.255x

Annual Cash Flow Conversion Efficiency for Autolus Therapeutics plc (2017–2025)

The table below shows the annual cash flow conversion efficiency of Autolus Therapeutics plc from 2017 to 2025. Review Autolus Therapeutics plc (6A3A) financial flexibility to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€178.13 Million ≈ $208.25 Million	€-283.57 Million ≈ $-331.52 Million	-1.592x	-229.79%
2024-12-31	€427.32 Million ≈ $499.59 Million	€-206.27 Million ≈ $-241.15 Million	-0.483x	+63.04%
2023-12-31	€111.47 Million ≈ $130.32 Million	€-145.59 Million ≈ $-170.21 Million	-1.306x	-247.32%
2022-12-31	€298.67 Million ≈ $349.18 Million	€-112.31 Million ≈ $-131.30 Million	-0.376x	+0.04%
2021-12-31	€313.32 Million ≈ $366.30 Million	€-117.86 Million ≈ $-137.79 Million	-0.376x	+32.91%
2020-12-31	€210.03 Million ≈ $245.55 Million	€-117.76 Million ≈ $-137.67 Million	-0.561x	-40.79%
2019-12-31	€254.84 Million ≈ $297.93 Million	€-101.48 Million ≈ $-118.65 Million	-0.398x	-139.23%
2018-12-31	€255.47 Million ≈ $298.67 Million	€-42.52 Million ≈ $-49.72 Million	-0.166x	-45.09%
2017-12-31	€142.60 Million ≈ $166.72 Million	€-16.36 Million ≈ $-19.13 Million	-0.115x	--

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$407.64 Million

€348.67 Million EUR

Market Cap Rank

#12983 Global

#1380 in Germany

Share Price

€1.31

Change (1 day)

-4.38%

52-Week Range

€1.06 - €2.16

All Time High

€40.10